Drug Trial Radar · NCT01004224
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Last checked: Nov 20, 2026Latest source record: Oct 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
208
Actual
Start
Dec 11, 2009
Primary completion
Oct 8, 2018
Study completion Oct 8, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 29, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety.
Conditions
- Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3
- Squamous Lung Cancer With FGFR1 Amplification
- Bladder Cancer With FGFR3 Mutation or Fusion
- Advanced Solid Tumors With FGFR1 Amplication
- Advanced Solid Tumors With FGFR2 Amplication
- Advanced Solid Tumors With FGFR3 Mutation
Interventions
BGJ398Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence rate and category of dose-limiting toxicities will be tabulated for patients included in the dose escalation portion of the study, to establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPTD)Time frame: 23 months
Locations
50 sites in 14 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Duarte, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Los Angeles, California
University of Colorado Dept. of Anschutz Cancer (3)
Aurora, Colorado
Novartis Investigative Site
New Haven, Connecticut
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Detroit, Michigan
Memorial Sloan Kettering Cancer Center Onc. Dept..
New York, New York
Novartis Investigative Site
New York, New York
Novartis Investigative Site
Columbus, Ohio
Novartis Investigative Site
Philadelphia, Pennsylvania
Thomas Jefferson University Hospital Onc Dept
Philadelphia, Pennsylvania
Novartis Investigative Site
Pittsburgh, Pennsylvania
Novartis Investigative Site
Memphis, Tennessee
Novartis Investigative Site
Nashville, Tennessee
Novartis Investigative Site
Salt Lake City, Utah
Novartis Investigative Site
Heidelberg, Victoria, Australia
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Saint-Herblain Cédex, France
Novartis Investigative Site
Suresnes, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Marburg, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Ramat Gan, Israel
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Meldola, FC, Italy
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Barcelona, Spain
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.